Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

Effect of Clozapine and Olanzapine on Neutrophil Kinetics: Implications for Drug-Induced Agranulocytosis

(2014) Winnie Ng et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

(2014) Massimiliano Buoli et al.   Expert Opinion on Drug Metabolism & Toxicology

Interethnic variability ofCYP2D6alleles and of predicted and measured metabolic phenotypes across world populations

(2014) Adrián LLerena et al.   Expert Opinion on Drug Metabolism & Toxicology

Selective Serotonin Reuptake Inhibitor Drug Interactions in Patients Receiving Statins

(2014) Chittaranjan Andrade   JOURNAL OF CLINICAL PSYCHIATRY

Meta-Analysis of Selective Serotonin Reuptake Inhibitor–Associated QTc Prolongation

(2014) Scott R. Beach et al.   JOURNAL OF CLINICAL PSYCHIATRY

Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder

(2013) Bernardo Dell'Osso et al.   Early Intervention in Psychiatry

New approaches to the pharmacological management of generalized anxiety disorder

(2013) Massimiliano Buoli et al.   EXPERT OPINION ON PHARMACOTHERAPY

Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases

(2012) Tomihisa Niitsu et al.   CURRENT PHARMACEUTICAL DESIGN

Newer antidepressants and panic disorder

(2012) Costanza Andrisano et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care

(2012) Borwin Bandelow et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers

(2012) Junji Saruwatari et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment

(2011) Martina Teichert et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of fluvoxamine on the pharmokinetics of zolpidem: A two-treatment period study in healthy volunteers

(2011) Laurian Vlase et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

(2011) Junichi Azuma et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Augmentative Effects of Fluvoxamine on Duloxetine Plasma Levels in Depressed Patients

(2011) M. Paulzen et al.   PHARMACOPSYCHIATRY

Effects of Cigarette Smoking and Cytochrome P450 2D6 Genotype on Fluvoxamine Concentration in Plasma of Japanese Patients

(2010) Yasuhiro Katoh et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics

(2010) Yutaro Suzuki et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Agomelatine in the treatment of panic disorder

(2010) Michele Fornaro   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Slow vs standard up-titration of paroxetine in the treatment of panic disorder: A prospective randomized trial

(2010) Massimiliano Buoli et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure

(2009) Rocco Orlando et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine

(2009) Evelyn D Lobo et al.   CLINICAL PHARMACOKINETICS

Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands

(2009) E. Cobos et al.   Current Neuropharmacology

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine–alprazolam interaction in patients with psychosomatic disease

(2009) Hideyo Sugahara et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and tolerability of second-generation antidepressants in social anxiety disorder

(2009) Richard A. Hansen et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition?

(2009) Stephen M. Stahl   JOURNAL OF CLINICAL PSYCHIATRY

Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression

(2009) Sandra Vezmar et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

The pharmacology of sigma-1 receptors

(2009) Tangui Maurice et al.   PHARMACOLOGY & THERAPEUTICS

Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors

(2009) Tsutomu Furuse et al.   Annals of General Psychiatry

Serotonin syndrome associated with sertraline, trazodone and tramadol abuse

(2009) Neha Nayyar   Indian Journal of Psychiatry

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update

(2008) Edoardo Spina et al.   CLINICAL THERAPEUTICS

Impact of Ovarian Hormones on the Modulation of the Serotonin Transporter by Fluvoxamine

(2008) Saloua Benmansour et al.   NEUROPSYCHOPHARMACOLOGY